Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.

Key facts

Study ID

NCT00100165

Run by

University of Colorado, Denver

People needed

29

Starts

2005-01-01

Expected to finish

2007-07-01

Last updated by the study team

2020-01-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Schizophrenia
• Currently treated with neuroleptic drugs

You may not qualify if…

• Treatment with clozapine;
• Head injury or neurological condition;
• Cardiovascular disease;
• Substance abuse or dependence, including nicotine

Where it is running

• VA Eastern Colorado Health Care System, Denver, CO — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.